Clinical Trials Directory

Trials / Completed

CompletedNCT01141036

Propofol Versus Midazolam for Upper Endoscopy in Cirrhotic Patients

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Ziv Hospital · Other Government
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Upper GI endoscopy is often performed in patients with chronic liver disease to screen for esophageal and gastric varices. The purpose of this study is to compare propofol to midazolam for sedation in patients with chronic liver disease undergoing diagnostic upper GI endoscopy.

Detailed description

Background : Upper GI endoscopy is often performed in patients with chronic liver disease to screen for esophageal and gastric varices. AIM: The purpose of this study is to compare propofol to midazolam for sedation in patients with chronic liver disease undergoing diagnostic upper GI endoscopy. Methods: 60 outpatients who has known chronic liver disease (Child-Pugh class A or B) (cirrhosis) and are undergoing variceal screening will be randomized to receive propofol or midazolam for sedation. Administration of sedation was performed by a anesthesist. Outcome measures studied are induction and recovery times, efficacy and safety of sedation, patient satisfaction, and return to baseline function and subclinical hepatic encephalopathy (number connection test), and saturation of oxygen. expected results: The mean time to achieve adequate sedation will be shorter for for the propofol group in comparison to midazolam group. The level of sedation achieved by the propofol group will be greater. Time to full recovery will be faster in the propofol group. Propofol do not exacerbate subclinical hepatic encephalopathy as compared to midazolam. patients receiving propofol will express greater overall mean satisfaction with the quality of their sedation at the time of discharge. Conclusions: Propofol sedation is expected not to exacerbate subclinical hepatic encephalopathy in cirrhotics.

Conditions

Interventions

TypeNameDescription
DRUGpropofolPropofol will be initiated with a 30-50 mg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
DRUGMidazolamMidazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved

Timeline

Start date
2008-07-01
Primary completion
2009-01-01
Completion
2009-02-01
First posted
2010-06-10
Last updated
2010-06-10

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT01141036. Inclusion in this directory is not an endorsement.